Pancreatic C-peptide response to oral glucose in fibrocalculous pancreatic diabetes. Improvement after treatment.
beta-Cell function (plasma C-peptide) in 17 fibrocalculous pancreatic diabetic (FCPD) subjects (14 newly diagnosed) was not different at presentation from that in 14 matched insulin-dependent diabetic subjects. After insulin treatment and improvement in the patients' nutritional and metabolic status, fasting and postglucose plasma C-peptide concentrations showed a significant increase (fasting 0.06 +/- 0.01 to 0.17 +/- 0.03 nM, peak 0.11 +/- 0.02 to 0.29 +/- 0.06 nM, mean +/- SE; P less than 0.01 for both). Thus, severely diminished beta-cell function in FCPD is partially reversible after treatment. This could contribute to the clinical metabolic peculiarities of this group of patients.
Yajnik
C S
CS
King Edward Memorial Hospital, Pune, India.
Kanitkar
S V
SV
Shelgikar
K M
KM
Naik
S S
SS
Alberti
K G
KG
Hockaday
D
D
D000328:Adult; D002096:C-Peptide / Q000097:blood* / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood; D005260:Female; D005355:Fibrosis; D005500:Follow-Up Studies; D005632:Fructose / Q000097:blood; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D010182:Pancreatic Diseases / Q000097:blood* / Q000473:pathology
D002096:C-Peptide; D005632:Fructose; D006442:Glycated Hemoglobin; D007328:Insulin